Idarubicin and idarubicinol effects on breast cancer multicellular spheroids

Journal of Chemotherapy

Volumn 17, Issue 6, 2005, Pages 663-667

  Orlandi, P ^a   Barbara, C ^a   Bocci, Guido ^a   Fioravanti, A ^a   Di Paolo, A ^a   Del Tacca, M ^a   Danesi, R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Idarubicin; Idarubicinol; MCF 7 breast cancer cells; Multicellular spheroids

Indexed keywords

DRUG METABOLITE; IDARUBICIN; IDARUBICINOL;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; EVALUATION; HUMAN; HUMAN CELL; IC 50; MONOLAYER CULTURE; MULTICELLULAR SPHEROID; SOLID TUMOR; SPHEROID CELL; TIME;

EID: 30744431872     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.6.663     Document Type: Article

References (24)

1. Thomlinson RH, Gray LH. The histological structure of some human lung cancer and the possible implications for radiotherapy. Br J Cancer 1955; 9: 539-47.
2. Kerr DJ, Kaye SB. Aspects of cytotoxic drug penetration, with particular reference to anthracyclines. Cancer Chemother Pharmacol 1987; 9: 1-5.
3. Simpson-Herren L, Noker PE. Diversity of penetration of anticancer agents into solid tumors. Cell Prolif 1991; 24: 355-65.
4. Sutherland RM. Cell and environment interactions in tumour microregions. Science 1988; 240: 177-84.
5. Mayer B, Klement G, Kaneko M et al. Multicellular gastric cancer spheroids recapitulate growth pattern and differentiation phenotype of human gastric carcinomas. Gastroenterology 2001; 121: 839-52.
6. Sutherland RM, Eddy HA, Bareham B et al. Resistance to adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys 1979; 5: 1225-30.
7. Erlanson M, Daniel-Szolgay E, Carlsson J. Relation between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids. Cancer Chemoter Pharmacol 1992; 29: 343-53.
8. Francia G, Man S, Teicher B et al. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents. Mol Cell Biol 2004; 24: 6837-49.
9. Gallois L, Fiallo M, Garnier-Suillerot A. Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Circular dichroism study. Biochim Biophys Acta 1998; 1370: 31-40.
10. Berens ME, Saito T, Welander CE et al. Antitumour activity of new anthracycline analogues in combination with Interferon alfa. Cancer Chemother Pharmacol 1987; 19: 301-6.
11. Borchmann P, Hubel K, Schnell R et al. Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther 1997; 35: 80-3.
12. Dodion P, Sanders C, Rombaut W, et al. Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxy-daunorubicinol against human normal myeloid stem cells and human malignant cells in vitro. Eur J Cancer Clin Oncol 1987; 23: 1909-14.
13. Glisson BS, Ross WE. DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol Ther 1987; 32: 69-106.
14. Capranico G, Riva A, Tinelli S et al. Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P338 leukemia cells and isolated nuclei. Cancer Res 1987; 47: 3752-6.
15. Cairo MS, Toy C, Sender L et al. Effect of idarubicin and epirubicin on in vitro polymorphonuclear function: diminished superoxide radical formation compared to their parent compounds daunorubicin and doxorubicin. J Leukoc Biol 1990; 47: 224-33.
16. Rang W, Weiss M. Modeling the metabolism of idarubicin to idarubicinol in rat heart: effect of rutin and phenobarbital. Drug Metab Dispos 2003; 31: 462-8.
17. Bengale C, Danesi R, Guarneri V et al. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. Bone Marrow Transplant 2003; 31: 275-80.
18. Toffoli G, Sorio R, Basso B et al. Pharmacokinetic comparison of 120-hour infusion versus hyperfractionated oral administration of idarubicin. J Chemother 2004; 16: 193-200.
19. Yuhas JM, Li AP, Martinez AO et al. A simplified method for production and growth of multicellular tumor spheroids. Cancer Res 1977; 37: 3639-43.
20. Chen FM, Liu CZ, Epstein AL. Effects of 1311-labeled TNT-1 radioimmunotherapy on HT-29 human colon adenocarcinoma spheroids. Cancer Immunol Immunother 1991; 33: 158-64.
21. Gewirtz DA, Randolph JK, Chawla J et al. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line. Cancer Chemother Pharmacol 1998; 41: 361-9.
22. Ross DD, Doyle LA, Yang W et al. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance. Biochem Pharmacol 1995; 50: 1673-83.
23. Ross DD, Gao Y, Yang W et al. The 95-kilodalton membrane glycoprotein overexpressed in novel multidrug-resistant breast cancer cells is NCA, the nonspecific cross-reacting antigen of carcinoembryonic antigen. Cancer Res 1997; 57: 5460-4.
24. Roovers DJ, van Vliet M, Bloem AC et al. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. Leuk Res 1999; 23: 539-48.